Oxford Science Enterprises’ Post

It is not easy to be a disruptor in an intrinsically conservative industry like pharma, but it is so much necessary for the future of medicine. It is a good sign that a key cell and gene therapy player entered the top 10 of CNBC Disruptors (a list where OpenAI has been first for two years in a row). Maybe more biotech disruptors in the top ten of this list in the future? For now, well done ElevateBio! With more than $ 1.25B raised, key R&D Partnerships with Pharma including Novo Nordisk, there is great potential to see new genetic medicines in areas like cancer and autoimmune diseases #celltherapy #genetherapy #ElevateBio #CNBCDisruptors #BiotechInnovation #FutureOfMedicine

Dyno Therapeutics launches its second product, Dyno eCap1 for the eye today at ESGCT. Congrats to the team on yet another best-in-class capsid for the treatment of genetic disease and beyond. Better delivery=Better treatments. Key Data on Dyno eCap 1 Technology -- The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid. -- The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile. -- The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells. -- The Dyno eCap 1 vector was validated in cynomolgus monkey (Macaca fascicularis), the most relevant NHP model for predicting translatability to human clinical trials. Improved performance is highly consistent across bulk RNA-seq, single-cell RNA-seq and histology.

10 days until Alliance for Regenerative Medicine’s #CGMesa23! Our team looks forward to connecting with senior executives and top stakeholders Oct 10-12 to tackle the most pressing issues in cell and gene therapies. Send us a partnering request to explore how we use our 3D-printed biomaterials platform to develop #regenerative therapeutics that boost cell viability and engraftment.  Learn more: https://lnkd.in/eiUpMy4

Dyno Therapeutics launches its second product, Dyno eCap1 for the eye today at ESGCT. Congrats to the team on yet another best-in-class capsid for the treatment of genetic disease and beyond. Better delivery=Better treatments. Key Data on Dyno eCap 1 Technology -- The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid. -- The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile. -- The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells. -- The Dyno eCap 1 vector was validated in cynomolgus monkey (Macaca fascicularis), the most relevant NHP model for predicting translatability to human clinical trials. Improved performance is highly consistent across bulk RNA-seq, single-cell RNA-seq and histology.

We can investigate drug sensitivity markers for your compound using the response parameters of cancer cell line profiling by performing analysis on IC50 values and gene mutation analysis to identify genomic drug response #biomarkers for cancer. Check out our four types of analysis: https://ow.ly/Mttp50QbMHg #bioinformatics #mutationanalysis

📆Day one at the 𝟑𝐫𝐝 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐏𝐨𝐭𝐞𝐧𝐜𝐲 𝐀𝐬𝐬𝐚𝐲 𝐒𝐮𝐦𝐦𝐢𝐭 in Boston and the Cellply team, Massimo Bocchi and Marco Fadda, are joining the many discussions about the challenges of potency assay development for these therapeutics. They are joining the many analytical, QC, and regulatory experts who are sharing insights into the real-world issue and assessing the impact of the FDA’s draft guidance “Potency assurance for cellular and gene therapy products”.   With VivaCyte now available commercially, there is a 𝐧𝐞𝐰 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐚𝐥 𝐨𝐩𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐝𝐞𝐞𝐩 𝐜𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐜𝐞𝐥𝐥𝐮𝐥𝐚𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 that offers novel insights to enhance understanding of these vital cell therapy products. 📍𝐁𝐎𝐎𝐓𝐇 #𝟒 #CellCharacterization #PotencyAssay #CellTherapy

EG 427 announces positive preclinical results from EG110A IND-enabling study in Neurogenic Detrusor Overactivity and Overactive Bladder. EG 427 today reports positive preclinical results from a dose escalation study of its gene therapy product EG110A for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). The data represents a pivotal milestone and paves the way for an Investigational New Drug (IND) application and initiation of the first clinical study of EG110A in early 2024. Access full Press Release in English and in French below. #genetherapy #incontinence #fundraising

Day 2 of #CICON23 and our team have been listening intently to the myriad challenges global researchers face in developing specific, effective and safe next-generation mono and combo immunotherapies for a wide range of difficult to treat tumours Whether in basic research, developing small or large molecules, cell and gene therapies or vaccines, and through the continuum of discovery, development to manufacturing scale-up and product QC/QA, we’re here to help you advance to your next inflection point! #cancerimmunotherapy #immunotherapy #immunecheckpoint

Things are now really starting to accelerate in this space - bring it on ..

Since 1987, we have assessed more than 1,000 cell banks and derived products with #InVitro assays. Thanks to the accurate and validated in vitro assays strategy in accordance with the ICH Q5A (R2), Texcell allows you to detect a broad panel of adventitious and emerging viruses using indicator dedicated cells. We are an innovative CRO and will assess the safety of your current bioproducts and your emerging cell and gene therapies. >>https://lnkd.in/e_X6MCXe<< #ProtectingTomorrowsMedicinesToday